Drug Profile
Research programme: peptide YY3-36 - Wyeth
Alternative Names: PYY3-36 - WyethLatest Information Update: 13 Aug 2009
Price :
$50
*
At a glance
- Originator Imperial Innovations; Oregon Health & Science University
- Developer Wyeth
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Neuropeptide Y2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 13 Aug 2009 No development reported - Preclinical for Obesity in United Kingdom (Parenteral)
- 18 Dec 2008 Thiakis has been acquired and merged into Wyeth
- 18 Aug 2005 Preclinical trials in Obesity in United Kingdom (Parenteral)